Publications & Posters

All categories

Publications

Posters

All Cell Engagers

AFM11

AFM13

AFM24

AFM26

All years

2019

2018

2017

2016

2015

2014

2013

2012

2011

2010

2009

Clinical and Biological Evaluation of the Novel CD30/CD16A Tetravalent Bispecific Antibody (AFM13) in Relapsed or Refractory CD30-Positive Lymphoma with Cutaneous Presentation: A Biomarker Phase Ib/IIa Study (NCT03192202).

Sawas et al.
ASH 2018 - AFM13-102

A Phase 1 Study Investigating AFM11 in Patients with Relapsed/Refractory B-cell Precursor Acute Lymphoblastic Leukemia: Preliminary Results

Salogub et al.
ASH 2018 - AFM11

A Phase 1 Study Investigating the Combination of AFM13 and the Monoclonal Anti-PD-1 Antibody Pembrolizumab in Patients with Relapsed/Refractory Hodgkin Lymphoma after Brentuximab Vedotin Failure: Updated Safety and Efficacy Data

Bartlett et al.
23rd Congress of EHA – AFM13

Pharmacokinetics and in vitro/in vivo characterization of high-affinity bispecific EGFR/CD16A NK cell engagers for the treatment of EGFR-expressing tumors

Kluge et al.
AACR 2018 – AFM24

Recombinant Antibodies to Arm Cytotoxic Lymphocytes in Cancer Immunotherapy.

J. Koch, M. Tesar
Transfus Med Hemother 2017; 44:337-350.

link to publication

Trispecific antibodies for CD16A-directed NK cell engagement and dual-targeting of tumor cells.

Gantke et al.
Protein Eng Des Sel. 2017 Aug 17:1-12. doi: 10.1093/protein/gzx043.

link to publication

AFM26 – Targeting BCMA for NK cell-mediated immunotherapy of multiple myeloma

Gantke et al.
ASH 2017 – AFM26

A Phase 1 Study Investigating the Combination of AFM13 and the Monoclonal Anti-PD-1 Antibody Pembrolizumab in Patients with Relapsed/Refractory Hodgkin Lymphoma after Brentuximab Vedotin Failure: Data from the Dose Escalation Part of the Study

Ansell et al.
ASH 2017 – AFM13

AFM26: A first-in-class, high affinity bispecific NK-cell engager targeting BCMA to treat multiple myeloma

Gantke et al.
EACR-AACR-SIC 2017 Special Conference

High affinity bispecific EGFR/CD16A antibodies specifically recruit NK-cells to target EGFR-expressing tumors

Kluge et al.
EACR-AACR-SIC 2017 Special Conference

1
2
3
4
5
6

We use cookies to give you the best experience on our website. By continuing to use it, you agree with it.